Teva to Present at the Deutsche Bank 36th Annual Health Care Conference

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Deutsche Bank 36th Annual Health Care Conference with Eyal Desheh, CFO, Teva Pharmaceutical Industries, and William Marth, President & CEO, Teva Pharmaceuticals - Americas, presenting on Wednesday, May 4, 2011 in Boston.

 

What:

    Teva Presentation at the Deutsche Bank 36th Annual Health Care Conference
 

Who:

Eyal Desheh, CFO, Teva Pharmaceutical Industries, and
William Marth, President & CEO, Teva Pharmaceuticals - Americas
 

When:

Wednesday, May 4, 2011 at 12:15pm ET
 

Where:

www.tevapharm.com/financial/ or

http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=TEVA&item_id=3960396

 

How:

Live over the Internet – log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.

 

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.



CONTACT:

IR:
Teva Pharmaceutical Industries Ltd.
Elana Holzman, 972 (3) 926-7554
or
Teva North America
Kevin C. Mannix, 215-591-8912
or
PR:
Teva Pharmaceutical Industries Ltd.
Yossi Koren, 972 (3) 926-7687
or
Teva North America
Denise Bradley, 215-591-8974

KEYWORDS:   United States  North America  New York  Middle East  Israel

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  General Health

MEDIA:

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.